Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al

Ann Rheum Dis. 2022 Nov;81(11):e223. doi: 10.1136/annrheumdis-2020-218910. Epub 2020 Sep 7.

Kimme L Hyrich¹, Milena Gianfrancesco², Pedro M Machado^{3

4}, Jinoos Yazdany⁵, Philip C Robinson^{6

7}

¹ Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK.
² Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, California, USA.
³ MRC Centre for Neuromuscular Diseases, University College London, London, UK.
⁴ Rheumatology, University College London Centre for Rheumatology, London, UK.
⁵ Medicine/Rheumatology, University of California, San Francisco, California, USA.
⁶ Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia [email protected].
⁷ Metro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia.

No abstract available

Keywords: autoimmunity; glucocorticoids; inflammation.

Publication types